Can knowing you and your family may get Alzheimer’s ever be positive?
By Giulia Rhodes,
The Guardian
| 09. 21. 2015
Untitled Document
At the University of Washington’s School of Medicine there is a computer database that states with certainty – albeit heavily encrypted – whether or not Sophie Leggett will develop a form of genetically inherited early onset Alzheimer’s disease. But she has chosen not to find out what it says.
A blood test is available to adult children and siblings of those who develop Alzheimer’s at a young age and have a family history of the disease. It identifies whether they carry one of the three faulty genes known to cause familial early onset Alzheimer’s, presenilin 1 (the mutation affecting Leggett’s family), presenilin 2 and amyloid precursor protein. All result in the overproduction of amyloid, a protein that builds up into the plaques on the brain which are the hallmark of Alzheimer’s.
Now 39, Leggett saw her mother and aunt develop familial early onset Alzheimer’s in their early 40s – as had their father. All died in their 50s. There is a one-in-two chance that Leggett has inherited the gene mutation.
“I focus on the 50% chance that...
Related Articles
By Josie Ensor, The Times | 12.09.2025
A fertility start-up that promises to screen embryos to give would-be parents their “best baby” has come under fire for a “misuse of science”.
Nucleus Genomics describes its mission as “IVF for genetic optimisation”, offering advanced embryo testing that allows...
By Hannah Devlin, The Guardian | 12.06.2025
Couples undergoing IVF in the UK are exploiting an apparent legal loophole to rank their embryos based on genetic predictions of IQ, height and health, the Guardian has learned.
The controversial screening technique, which scores embryos based on their DNA...
By Frankie Fattorini, Pharmaceutical Technology | 12.02.2025
Próspera, a charter city on Roatán island in Honduras, hosts two biotechs working to combat ageing through gene therapy, as the organisation behind the city advertises its “flexible” regulatory jurisdiction to attract more developers.
In 2021, Minicircle set up a...
By Vardit Ravitsky, The Hastings Center | 12.04.2025
Embryo testing is advancing fast—but how far is too far? How and where do we draw the line between preventing disease and selecting for “desirable” traits? What are the ethical implications for parents, children, clinicians, and society at large? These...